Log in

VTX:NOVNNovartis Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume11.21 million shs
Average Volume5.98 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Novan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. The company's clinical stage product candidates comprise SB208, a topical antifungal gel that is in Phase II proof-of-concept trial for the treatment of athlete's foot and fungal nail infections; and SB414, a topical cream, which is in Phase Ib trial for the treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis. It has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. has a strategic alliance with Orion Corporation to manufacture topical nitric oxide-releasing product candidates. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.
Read More
Novartis logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.1Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.24 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+41-61-3241111

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees47
Next Earnings DateN/A
OptionableNot Optionable

Receive NOVN News and Ratings via Email

Sign-up to receive the latest news and ratings for NOVN and its competitors with MarketBeat's FREE daily newsletter.

Novartis (VTX:NOVN) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Novartis?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 2 sell ratings, 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Novartis.

What price target have analysts set for NOVN?

13 Wall Street analysts have issued 12-month price targets for Novartis' shares. Their forecasts range from CHF 70 to CHF 110. On average, they anticipate Novartis' stock price to reach CHF 92.77 in the next year. View analysts' price targets for Novartis.

Has Novartis been receiving favorable news coverage?

News stories about NOVN stock have trended very positive recently, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novartis earned a coverage optimism score of 4.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View the latest news aboutNovartis.

Who are some of Novartis' key competitors?

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Novartis (NVS), General Motors (GM), Iamgold (IAG), DigitalGlobe (DGI), Kraft Heinz (KHC), Mastercard (MA), Bank of America (BAC), Delta Air Lines (DAL), General Electric (GE) and SAP (SAP).

Who are Novartis' key executives?

Novartis' management team includes the following people:
  • Mr. G. Kelly Martin, CEO & Director (Age 60)
  • Ms. Paula Brown Stafford, Pres, COO & Director (Age 54)
  • Mr. John M. Gay, VP of Fin., Corp. Controller, Principal Financial Officer and Corp. Sec. (Age 42)
  • Dr. Nathan Stasko, Co-Founder & Chief Scientific Officer (Age 39)
  • Dr. Carri Geer, Sr. VP & CTO

What is Novartis' stock symbol?

Novartis trades on the VTX under the ticker symbol "NOVN."

What is Novartis' official website?

The official website for Novartis is www.novartis.com.

How can I contact Novartis?

Novartis' mailing address is Lichtstrasse 35, BASEL, 4056, Switzerland. The company can be reached via phone at +41-61-3241111.

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.